Dopamine D1B receptor chimeras reveal modulation of partial agonist activity by carboxyl-terminal tail sequences.
NNC 01-0012, a second-generation benzazepine compound, pharmacologically differentiates multiple vertebrate D1 receptor subtypes (D1A, D1B, D1C, and D1D) and displays high selectivity and affinity for dopamine D1C receptors. Functionally, whereas NNC 01-0012 acts as a full or poor antagonist at D1C and D1A receptor-mediated cyclic AMP production, respectively, it exhibits partial agonist activity at the D1B receptor. To define some of the structural motifs that regulate the pharmacological and functional differentiation of vertebrate dopamine D1 receptors by NNC 01-0012, a series of receptor chimeras were constructed in which the divergent carboxyl-terminal (CT) receptor tails were replaced with the corresponding sequences of D1A, D1B, or D1C receptors. Substitution of the vertebrate D1B carboxyl-terminal-tail at position Tyr345 with carboxyl-terminal-tail sequences of the D1A receptor abolished the partial agonist activity of NNC 01-0012 without affecting dopamine-stimulated cyclic AMP accumulation. At vertebrate D1B/D1CcT-tail receptor mutants, however, the intrinsic activity of the partial agonist NNC 01-0012 (10 microM) was markedly enhanced (approximately 60% relative to 10 microM dopamine) with no concomitant alteration in the molecule's ligand binding affinity or constitutive activity of the chimeric receptor. Similar results were obtained with other benzazepines such as SKF-38393 and SCH-23390, which act as partial agonists at vertebrate D1B receptors. Substitution of D1A and D1C receptor carboxyl-terminal tails with sequences encoded by the D1B receptor carboxyl-terminal tail did not, however, produce receptors with functional characteristics significantly different from wild type. Taken together, these data clearly suggest that in addition to well-characterized domains and amino acid residues in the third cytoplasmic loop, partial agonist activity at the D1B receptor is modulated by sequence-specific motifs within the carboxyl-terminal tail, a region that may underlie the possible structural basis for functionally divergent roles of multiple dopamine D1-like receptors.
Sugamori
K S
KS
Department of Pharmacology, University of Toronto, Centre for Addiction and Mental Health, Ontario, Canada.
Scheideler
M A
MA
Vernier
P
P
Niznik
H B
HB
D000818:Animals; D001552:Benzazepines / Q000819:agonists / Q000494:pharmacology; D001667:Binding, Competitive; D019556:COS Cells; D002678:Chimera / Q000235:genetics*; D000242:Cyclic AMP / Q000378:metabolism; D018492:Dopamine Antagonists / Q000494:pharmacology; D008024:Ligands; D009154:Mutation / Q000502:physiology; D017447:Receptors, Dopamine D1 / Q000819:agonists* / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D050641:Receptors, Dopamine D5
D001552:Benzazepines; D018492:Dopamine Antagonists; D008024:Ligands; C114704:NNC 01-0012; D017447:Receptors, Dopamine D1; C098593:dopamine D1A receptor; C100987:dopamine D1C receptor; D050641:Receptors, Dopamine D5; D000242:Cyclic AMP